1Allen J,JahanzebMJ,NatlComper,et al.Neoadjuvant Chemotherapy in StageⅢ NSCLC.Lung Cancer,2008,6:285-293.
2Chandra V,Allen MS,Nichols FC 3rd,et al.The role of pulmonary reaction in Small cell lung cancer.Mayo Clin Proc,2006,81:619-623.
3Schreiber D,Rineer J,Vongtama D,et al.Surgery for limited stage Small cell lung cancer,should the paracligm shift'?.A seer based analsis.J Clin Oncal,2008,26:a7525-7529.
4Dan L,Zhu B,Chen Z.Meta-analysis of the literature:Neoadjuvant chemotherapy versus surgery alone in non-small cell lung cancer.J Clin Oncol,2008,26:a7598-7602.
5Chevalier TLe,Dunant A,Arriagada R,et al.Long-team results of the international Adjuvant Lung Cancer Trial(IALT)evalusting adjuvant cisplatin-based chemotherapy in reseted non-small cell lung cancer(NSCLC).J Clin Oncol,2008,26:a7507-7513.
6Maione P,Rossi A,Airoma G,et al.The role of targeted therapy in NSCLC.Cfit Rev Oncol Hematol,2004,51:29-44.
7Fried DB,Morris DE,Poole C,et al.Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stsged Small cell lung cancer.J Clin Oncol,2004,22:4837-4845.
8Twombly R.Failing Survival advantage in crucical trial,future of Iressa is in jeopardy.Natl Cancer Inst,2005,97:249-250.
9Kim ES,Hirsh V,Mok T,et al.Gefitinib versus docetaxel in previously treated non-small-cell lung cancer(INTEREST):a rsndomised phase Ⅲ trial.Lancet,2008,372:1809-1818.
10Park K,Lee JS,Wu YL,et al.Interim Salary results from the East/South East(E/SE)Asian Subgroup of the open label TRUST(TaR cevalung Cancer Survial Treatment)study of erlotinib for advanced nonsmall-cell lung cancer(NSCLC).J Thoracic On col,2007,2:S464-465.
3[9]Wong R,Sagar CM,Sagar SM.Integraion of Chinese medicine into sup-portive cancer care:a modem role forrole for an ancient tradition[J].CancerTreat Rev,2001,27(4).
